legislation

Evolution step-up growth trajectory upward trajectory
Pharma

How biosimilar developers are embracing next phase of US market

Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
Capitol building in Washington
Favicon Fierce Biotech

A divisive bill seeks to limit biotech investment in China

Jun 4, 2026 10:54am
The White House

White House touts $529B in MFN savings over 10 years

May 6, 2026 10:32am
FDA

FDA seeks powers to bite back against misleading DTC drug ads

Apr 7, 2026 9:03am
WuXi

WuXi Bio's contracting business saw influx of US clients in '25

Mar 24, 2026 10:56am
Maryland state house flag

Md. bill calls for transparency in disease awareness campaigns

Mar 19, 2026 12:04pm